Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging trial of OPC-249 inhalation in osteoporosis-related pain
jRCT2080220414Phase 2
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2007
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of OPC-249 in osteoporosis and vertebral compression fracture (VCF), sponsored by Otsuka Pharmaceutical Co., Ltd.
02
Drugs
OPC-249
03
Conditions
osteoporosisvertebral compression fracture (VCF)
Beyond the preview
Go deeper on jRCT2080220414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220414.